"The voice of oncology in Massachusetts."

FDA grants accelerated approval to pemigatinib (Pemazyre) for cholangiocarcinoma with an FGFR2 rearrangement or fusion

April 21, 2020 9:06 AM | Anonymous

The Food and Drug Administration granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. Read full press release

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software